We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Continuation Treatment Protocol for Patients Who Participated in the Adagio TVP 1012/501 Clinical Trial

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2012 by Rabin Medical Center.
Recruitment status was:  Not yet recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01709461
First Posted: October 18, 2012
Last Update Posted: October 18, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Rabin Medical Center
  Purpose
the purpose of the study is to extend the use of Rasagelin Mesylate 1mg per day by subjects who participated in the Adagio TVP 1012/501 according to form 4a for additional three years.

Condition
Parkinson Disease

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Continue Providing Care for Patient Who Participated in the Adagio TVP 1012/501 Clinical Trial

Resource links provided by NLM:


Further study details as provided by Rabin Medical Center:

Estimated Enrollment: 12
Study Start Date: October 2012
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
subjects who took part in the TVP 1012/501 clinical trial and willing to contiue receiving Rasgiline Mesylate.
Criteria

Inclusion Criteria:

  • subjects who are willing to contiue this treatment.
  • subjects who took part in the TVP 1012/501 clinical trail.

Exclusion Criteria:

  • subjects who didn't take part in the TVP 1012/501 clinical trail.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01709461


Contacts
Contact: Ruth Djaldetti, Professor 972-9378218/9 ruthdjal@clalit.org.il
Contact: Yaniv roditi, Msc 972-39236843 yar@clalit.org.il

Locations
Israel
Rabin Medical Center Beilinson Campus Not yet recruiting
Petach Tiqva, Hamerkaz, Israel, 49100
Principal Investigator: Ruth Djaldetti, Professor         
Sponsors and Collaborators
Rabin Medical Center
  More Information

Responsible Party: Rabin Medical Center
ClinicalTrials.gov Identifier: NCT01709461     History of Changes
Other Study ID Numbers: RD 06 - 12
First Submitted: October 14, 2012
First Posted: October 18, 2012
Last Update Posted: October 18, 2012
Last Verified: June 2012

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases